Description

Letrozol-TEVA Coated Tablets 2.5 mg. №30

Ingredients:

Each coated tablet contains 2.5 mg of Letrozole.

Dosage:

The recommended dosage is one 2.5 mg tablet daily, or as directed by a healthcare professional.

Indications:

Letrozol-TEVA is indicated for the treatment of hormone receptor-positive early breast cancer in postmenopausal women.

Contraindications:

Do not use Letrozol-TEVA if you are pregnant, breastfeeding, or allergic to Letrozole.

Directions:

Swallow the tablet whole with a glass of water, with or without food, at the same time each day.

Scientific Evidence:

Letrozole, the active ingredient in Letrozol-TEVA, is an aromatase inhibitor that works by reducing the production of estrogen in the body. This mechanism of action has been shown to be effective in the treatment of hormone receptor-positive breast cancer. Clinical trials have demonstrated the superior efficacy of Letrozole over tamoxifen in improving disease-free survival and reducing the risk of cancer recurrence.

Additional Information:

It is important to follow the prescribed dosage and schedule when taking Letrozol-TEVA to achieve optimal treatment outcomes. Consult your healthcare provider for any questions or concerns regarding the use of this medication. Letrozol-TEVA may cause side effects such as hot flashes, fatigue, and joint pain. If you experience any severe or persistent side effects, seek medical attention immediately.

Research studies have highlighted the benefits of Letrozole in improving overall survival rates and quality of life in postmenopausal women with hormone receptor-positive breast cancer. The drug’s favorable safety profile and efficacy make it a valuable option in adjuvant therapy for breast cancer patients.